The prevention of mortality after botulinum toxin injection in oral maxillofacial region |
Lee, Won-Kang
(Department of Orofacial Pain & Oral Medicine, College of Dentistry, Yonsei University)
Choi, Young-Chan (Department of Orofacial Pain & Oral Medicine, College of Dentistry, Yonsei University) Choi, Moon-Jong (Sarangmaeul Psychiatric Clinic) Kim, Seong-Taek (Department of Orofacial Pain & Oral Medicine, College of Dentistry, Yonsei University) |
1 | Al-Saleem FH, Ancharski DM, Ravichandran E, Joshi SG, Singh AK, Gong Y, Simpson LL. The role of systemic handling in the pathophysiologic action of botulinum toxin. J Pharmacol Exp Ther 2008;326:856-63. DOI ScienceOn |
2 | Al-Saleem FH, Nasser Z, Olson RM, Cao L, Simpson LL. Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J Pharmacol Exp Ther 2011;338:503-17. DOI ScienceOn |
3 | Sheth AN, Wiersma P, Atrubin D, Dubey V, Zink D, Skinner G, Doerr F, Juliao P, Gonzalez G, Burnett C, Drenzek C, Shuler C, Austin J, Ellis A, Maslanka S, Sobel J. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis 2008;47:1245-51. DOI ScienceOn |
4 | Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 2003;10:13-8. DOI ScienceOn |
5 | Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 2007;44:1029-41. DOI ScienceOn |
6 | Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies-therapeutic consequences. Exp Neurol 1997;147:96-102. DOI ScienceOn |
7 | Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009;32:213-8. DOI ScienceOn |
8 | Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm 2013;120:275-90. DOI ScienceOn |
9 | Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic case. J Am Acad Dermatol 2005;53:407-15. DOI ScienceOn |
10 | Simpson L. The life history of a botulinum toxin molecule. Toxicon 2013;68:40-59. DOI ScienceOn |
11 | Lamanna C. The most poisonous poison. Science 1959;130:763-72. DOI ScienceOn |
12 | Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-93. DOI ScienceOn |
13 | Elias M, Al-Saleem FH, Ancharski DM, Singh A, Nasser Z, Olson RM, Simpson LL. Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine. J Pharmacol Exp Ther 2011;336:605-12. DOI ScienceOn |
14 | Ravichandran E, Gong Y, Al-Saleem FH, Ancharski DM, Joshi SG, Simpson LL. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 2006;318:1343-51. DOI ScienceOn |